Brind.

Vaxart appointed Steven Lo as Chief Executive Officer and Michael J. Finney as Chairman of the Board on September 3, 2025.

5 reports, 1 independent Updated Sep 3
Gone quiet
Reports
5
Developments
3
Repetition
40%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Vaxart appointed Steven Lo as Chief Executive Officer and Michael J. Finney as Chairman of the Board on September 3, 2025.

Who's involved

What this event is mainly about

How it developed

Newest first. Tap a step to see who reported it.
  1. Vaxart appointed Steven Lo as CEO and Michael J. Finney as Chairman of the Board.1 source
  2. ISS supported Vaxart's reverse stock split proposal.1 source
  3. Vaxart listed on OTCQX Best Market and confirmed Steven Lo as CEO.

Keep exploring

The entities involved

  • Vaxart

    American biotechnology company based in San Francisco

    Nothing else this week.

  • Steven Lo

    Hong Kong businessman

    Nothing else this week.

Coverage

Newest first; wire copies grouped
  • GlobeNewswireVaxart Announces Retirement of Chairman Michael J. Finney, Ph.D. from the Board of Directors SOUTH SAN FRANCISCO, Calif., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX: VXRT) (“Vaxart” or th
  • GlobeNewswireConcerned Vaxart Stockholders Urge Fellow Stockholders to Vote “AGAINST” Reverse Stock Split and Demand Board Accountability Oppose Management’s Latest Attempt to Push Through Proposal Despite Prior
  • GlobeNewswireVaxart to Host Virtual Stockholder Fireside Chat on Wednesday, August 20 to Discuss Reverse Stock Split Proposal - ISS and Glass Lewis, leading independent proxy advisory firms, support reverse stock
  • GlobeNewswireVaxart Provides Business Update and Reports Second Quarter 2025 Financial Results Reported positive topline data from Phase 1 clinical trial evaluating Company’s second-generation oral norovirus vacc
  • Unknown outlet